What is Revelation Biosciences, Inc. Warrant's earnings per share (EPS)?

Revelation Biosciences, Inc. Warrant (REVBW) reported diluted earnings per share of -$23.95 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Revelation Biosciences, Inc. Warrant (REVBW) Financials

REVBW

FY2025 annual

Revenue Not reported for FY2025

Net Income -$8.9M +40.7% YoY

EPS (Diluted) -$23.95 YoY not available

Operating Cash Flow -$8.3M +54.9% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the REVBW SEC filings page.

This page shows Revelation Biosciences, Inc. Warrant (REVBW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI REVBW FY2025 2026-08-29

External financing, not operating cash generation, is the dominant mechanic supporting a business with recurring operating losses.

In FY2025, operating cash flow was -$8.3M while financing cash flow supplied $12.5M; balance-sheet liquidity is being built through financing, not cash generation. The current ratio reached 5.4x, but that improvement must be read alongside ongoing losses: more current assets relative to liabilities does not mean operations fund themselves.

In FY2025, SG&A and R&D totaled $9.1M, essentially matching the $9.1M operating loss; with revenue unreported, the statements expose spending intensity but not commercial output. R&D was $5.4M in FY2022 and $4.1M in FY2025, so the lower loss does not represent a completed shift away from development spending.

FY2024 net loss of $15.0M was far larger than its $8.0M operating loss, whereas FY2025 net and operating losses nearly converged; earnings quality improved because the non-operating gap did not persist. Debt-to-equity also fell from 0.4x to 0.3x, indicating a less debt-dependent balance sheet even as equity remains shaped by financing.

Financial Health Signals

Financial health score not available

Revelation Biosciences, Inc. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Revelation Biosciences, Inc. Warrant passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Revelation Biosciences, Inc. Warrant reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$3.7M

YoY-48.9%

QoQ-18.4%

Revelation Biosciences, Inc. Warrant's EBITDA was -$3.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 48.9% from the same quarter a year earlier. Against the prior quarter it is down 18.4%.

Net Income

-$3.3M

YoY-36.0%

QoQ-10.4%

Revelation Biosciences, Inc. Warrant reported -$3.3M in net income in Q2 2026. This represents a decrease of 36.0% from the same quarter a year earlier. Against the prior quarter it is down 10.4%.

EPS (Diluted)

-$0.87

Revelation Biosciences, Inc. Warrant earned -$0.87 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$2.6M

QoQ+21.0%

Revelation Biosciences, Inc. Warrant recorded an outflow of $2.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is up 21.0%.

Cash & Debt

$11.5M

YoY+121.9%

QoQ-18.6%

5Y CAGR+12.5%

Revelation Biosciences, Inc. Warrant held $11.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

5Y CAGR-13.0%

Revelation Biosciences, Inc. Warrant had 4M shares outstanding in Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-33.0%

YoY+30.9pp

QoQ-9.8pp

Revelation Biosciences, Inc. Warrant's ROE was -33.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 30.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.9M

YoY+45.6%

QoQ+39.3%

Revelation Biosciences, Inc. Warrant invested $1.9M in research and development in Q2 2026. This represents an increase of 45.6% from the same quarter a year earlier. Against the prior quarter it is up 39.3%.

Capital Expenditures

$40K

QoQ-44.9%

Revelation Biosciences, Inc. Warrant invested $40K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 44.9%.

Share Buybacks

Not reported for Q2 2026.

REVBW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REVBW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
R&D Expenses	N/A	$4.1M+14.5%	$3.5M-14.4%	$4.1M-22.9%	$5.4M-22.2%	$6.9M	N/A	N/A
SG&A Expenses	N/A	$5.0M+13.1%	$4.4M-1.9%	$4.5M-17.8%	$5.5M+9.0%	$5.0M+3361.2%	$145K	N/A
Operating Income	N/A	-$9.1M-13.7%	-$8.0M+7.9%	-$8.7M+20.3%	-$10.9M	N/A	N/A	N/A
EBITDA	N/A	-$9.0M-13.8%	-$7.9M+7.9%	-$8.6M+20.4%	-$10.8M	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	$42K	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	N/A	N/A
Net Income	N/A	-$8.9M+40.7%	-$15.0M-12405.6%	-$120K+98.9%	-$10.8M	N/A	-$1.6M-44718.6%	-$4K
EPS (Basic)	N/A	-$23.95+97.7%	-$1052.16-12366.4%	-$8.44+94.3%	-$149.20-251.1%	-$42.50-6150.0%	-$0.68	N/A
EPS (Diluted)	—	-$23.95	-$1052.16	-$8.44	-$149.20	-$42.50	N/A	N/A
Diluted Shares (Avg)	N/A	620,785	14,293	14,246	72,585	282,035	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$1.9M+45.6%	$1.4M+60.3%	N/A	$923K+11.1%	$1.3M-5.5%	$859K+19.7%	N/A	$831K-49.7%
SG&A Expenses	$1.7M+52.5%	$1.7M+38.8%	N/A	$1.0M+5.6%	$1.1M+1.4%	$1.2M+4.4%	N/A	$966K-14.3%
Operating Income	-$3.7M-48.8%	-$3.1M-47.6%	N/A	-$1.9M-8.1%	-$2.5M+2.4%	-$2.1M-10.1%	N/A	-$1.8M+35.3%
EBITDA	-$3.7M-48.9%	-$3.1M-47.8%	N/A	-$1.9M-8.2%	-$2.5M+2.4%	-$2.1M-10.1%	N/A	-$1.8M+35.4%
Interest Expense	$82K+317.6%	N/A	N/A	N/A	$20K	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	$0	N/A	$0	N/A	$0
Net Income	-$3.3M-36.0%	-$3.0M-46.7%	N/A	-$1.9M+14.9%	-$2.4M+70.9%	-$2.1M+23.5%	N/A	-$2.2M+14.7%
EPS (Basic)	-$0.87+96.9%	-$2.71+89.3%	-$14.19+98.0%	-$1.77+95.6%	-$28.04+88.6%	-$25.34+35.6%	-$698.11-6777.9%	-$40.15-303.9%
EPS (Diluted)	-$0.87	-$2.71	-$14.19	-$1.77	-$28.04	-$25.34+35.6%	-$698.11	-$40.15
Diluted Shares (Avg)	4M	3M	N/A	3M	200,668	80,943+18.8%	N/A	55,832

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

REVBW Balance Sheet

REVBW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Total Assets	$11.6M+74.9%	$6.6M-45.8%	$12.2M+121.9%	$5.5M+169.5%	$2.0M-97.2%	$74.2M+327023.7%	$23K
Current Assets	$10.8M+64.7%	$6.6M-46.0%	$12.1M+124.4%	$5.4M+183.1%	$1.9M+193.6%	$651K+2772.8%	$23K
Cash & Equivalents	$10.7M+64.6%	$6.5M-45.8%	$12.0M+128.3%	$5.3M+312.1%	$1.3M+10763.6%	$12K	N/A
Short-Term Investments	$0	$0	$0	$0	$0-100.0%	$525K	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	N/A
Total Liabilities	$2.7M+42.2%	$1.9M-65.6%	$5.6M+25.0%	$4.5M+107.8%	$2.1M-97.0%	$70.8M+268821.6%	$26K
Current Liabilities	$2.0M+4.4%	$1.9M-65.6%	$5.6M+25.0%	$4.5M+107.8%	$2.1M-37.6%	$3.4M+12951.2%	$26K
Non-Current Liabilities	$724K	$0	$0	$0	$0-100.0%	$67.3M	$0
Total Equity	$8.9M+88.2%	$4.7M-29.2%	$6.6M+531.6%	$1.1M+1158.1%	-$99K-102.9%	$3.4M+93877.5%	-$4K
Retained Earnings	-$49.4M-22.0%	-$40.5M-59.1%	-$25.5M-0.5%	-$25.3M-74.6%	-$14.5M-155.0%	-$5.7M-156410.4%	-$4K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$12.5M+131.7%	$15.0M+278.9%	$11.6M+74.9%	$12.9M+90.7%	$5.4M-56.0%	$4.0M-73.0%	$6.6M-45.8%	$6.7M-52.6%
Current Assets	$11.7M+118.0%	$14.2M+261.7%	$10.8M+64.7%	$12.8M+92.7%	$5.4M-56.1%	$3.9M-73.1%	$6.6M-46.0%	$6.7M-52.9%
Cash & Equivalents	$11.5M+121.9%	$14.1M+281.0%	$10.7M+64.6%	$12.7M+94.3%	$5.2M-57.1%	$3.7M-74.5%	$6.5M-45.8%	$6.5M-53.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.4M+54.9%	$2.1M+88.6%	$2.7M+42.2%	$1.9M-54.4%	$1.6M-85.9%	$1.1M-79.2%	$1.9M-65.6%	$4.1M-24.7%
Current Liabilities	$1.9M+19.8%	$1.4M+30.1%	$2.0M+4.4%	$1.9M-54.4%	$1.6M-85.9%	$1.1M-79.2%	$1.9M-65.6%	$4.1M-24.7%
Non-Current Liabilities	$551K	$638K	$724K	$0	$0	$0	$0	$0
Total Equity	$10.1M+163.1%	$13.0M+350.9%	$8.9M+88.2%	$11.0M+311.5%	$3.8M+235.5%	$2.9M-69.6%	$4.7M-29.2%	$2.7M-69.7%
Retained Earnings	-$55.8M-23.9%	-$52.4M-23.2%	-$49.4M-22.0%	-$46.9M-21.0%	-$45.0M-23.2%	-$42.6M-51.2%	-$40.5M-59.1%	-$38.8M-66.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

REVBW Cash Flow Statement

REVBW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Cash Flow	-$9.3M	-$8.3M+54.9%	-$18.3M-151.4%	-$7.3M+35.1%	-$11.2M	N/A	-$217K	N/A
Depreciation & Amortization	N/A	$27K-3.1%	$28K+11.5%	$25K0.0%	$25K+49.3%	$17K	N/A	N/A
Stock-Based Compensation	N/A	$595K+252.6%	$169K+8.4%	$156K-48.3%	$301K-36.1%	$471K	N/A	N/A
Capital Expenditures	N/A	N/A	$19K	N/A	N/A	$132K	N/A	N/A
Free Cash Flow	N/A	N/A	-$18.3M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	-$19K	N/A	N/A	-$132K+99.8%	-$74.0M	N/A
Financing Cash Flow	$15.7M	$12.5M-2.9%	$12.8M-8.4%	$14.0M-7.7%	$15.2M+89.9%	$8.0M-89.2%	$74.3M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.6M-33.2%	-$3.2M-15.0%	-$2.0M+47.5%	-$1.6M+82.8%	-$1.9M+22.6%	-$2.8M+1.5%	-$3.7M-87.1%	-$9.3M-439.2%
Depreciation & Amortization	$8K+15.1%	$7K-0.2%	$6K-19.0%	$7K-6.3%	$7K0.0%	$7K+15.3%	$7K+15.3%	$7K+15.3%
Stock-Based Compensation	$401K+45881.3%	$471K+110.8%	N/A	$874-97.3%	$873-97.3%	$223K+596.3%	N/A	$32K0.0%
Capital Expenditures	$40K	$72K	N/A	N/A	N/A	N/A	-$18K	$18K
Free Cash Flow	-$2.6M	-$3.3M	N/A	N/A	N/A	N/A	-$3.8M	-$9.3M-440.3%
Investing Cash Flow	-$40K	-$72K	N/A	N/A	N/A	N/A	$18K	-$18K
Financing Cash Flow	-$34K	$6.7M	-$41K-101.1%	$9.1M+143.8%	N/A	N/A	$3.7M	$3.7M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

REVBW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REVBW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Return on Equity	-100.6%+218.8pp	-319.4%-317.6pp	-1.8%+1027.2pp	-1029.0%	N/A	-47.8%	N/A
Return on Assets	-77.0%+150.1pp	-227.1%-226.1pp	-1.0%+195.8pp	-196.8%	N/A	-2.2%+13.9pp	-16.1%
Current Ratio	5.41+2.0x	3.43+1.2x	2.18+1.0x	1.22+0.3x	0.89+0.7x	0.19-0.7x	0.86
Debt-to-Equity	0.31-0.1x	0.41-0.4x	0.84-3.4x	4.23	N/A	20.74	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-33.0%+30.9pp	-23.2%+48.0pp	N/A	-17.3%+66.5pp	-63.9%+671.8pp	-71.2%-42.9pp	N/A	-83.8%-54.0pp
Return on Assets	-26.6%+18.7pp	-20.0%+31.7pp	N/A	-14.8%+18.4pp	-45.3%+23.1pp	-51.7%-33.4pp	N/A	-33.3%-14.8pp
Current Ratio	6.21+2.8x	10.02+6.4x	5.41+2.0x	6.92+5.3x	3.42+2.3x	3.61+0.8x	3.43+1.2x	1.64-1.0x
Debt-to-Equity	0.24-0.2x	0.16-0.2x	0.31-0.1x	0.17-1.4x	0.41-9.3x	0.38-0.2x	0.41-0.4x	1.52+0.9x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Revelation Biosciences, Inc. Warrant REVBW	FY2025	N/A	-$8.9M	N/A	N/A	—
Aspire-Lakewood Holdings, Inc. Warrant ASBPW	FY2025	$6K	N/A	N/A	N/A	—
BriaCell Therapeutics Corp. Warrant BCTXW	FY2025	N/A	-$26.3M	N/A	N/A	—
BriaCell Therapeutics Corp. Warrant BCTXZ	FY2025	N/A	-$26.3M	N/A	N/A	—

Where Revelation Biosciences, Inc. Warrant Ranks

Frequently Asked Questions

Is Revelation Biosciences, Inc. Warrant profitable?

No, Revelation Biosciences, Inc. Warrant (REVBW) reported a net income of -$8.9M in fiscal year 2025.

What is Revelation Biosciences, Inc. Warrant's EBITDA?

Revelation Biosciences, Inc. Warrant (REVBW) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Revelation Biosciences, Inc. Warrant's return on equity (ROE)?

Revelation Biosciences, Inc. Warrant (REVBW) has a return on equity of -100.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Revelation Biosciences, Inc. Warrant's operating cash flow?

Revelation Biosciences, Inc. Warrant (REVBW) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Revelation Biosciences, Inc. Warrant's total assets?

Revelation Biosciences, Inc. Warrant (REVBW) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Revelation Biosciences, Inc. Warrant spend on research and development?

Revelation Biosciences, Inc. Warrant (REVBW) invested $4.1M in research and development during fiscal year 2025.

How many shares does Revelation Biosciences, Inc. Warrant have outstanding?

Revelation Biosciences, Inc. Warrant (REVBW) had 4M shares outstanding as of fiscal year 2025.

What is Revelation Biosciences, Inc. Warrant's current ratio?

Revelation Biosciences, Inc. Warrant (REVBW) had a current ratio of 5.41 as of fiscal year 2025, which is generally considered healthy.

What is Revelation Biosciences, Inc. Warrant's debt-to-equity ratio?

Revelation Biosciences, Inc. Warrant (REVBW) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Revelation Biosciences, Inc. Warrant's return on assets (ROA)?

Revelation Biosciences, Inc. Warrant (REVBW) had a return on assets of -77.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Revelation Biosciences, Inc. Warrant's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Revelation Biosciences, Inc. Warrant (REVBW) held $10.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.3M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Revelation Biosciences, Inc. Warrant's Piotroski F-Score?

Revelation Biosciences, Inc. Warrant (REVBW) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Revelation Biosciences, Inc. Warrant's earnings high quality?

Revelation Biosciences, Inc. Warrant (REVBW) reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.